ENXTAM:PHARMBiotechs
Pharming Group (ENXTAM:PHARM) Valuation After Upgraded 2025 Earnings Guidance And Revenue Outlook
Why Pharming Group’s latest guidance move matters
Pharming Group (ENXTAM:PHARM) lifted its 2025 earnings guidance. The company now forecasts around US$376 million in revenue, above its earlier range and tied to RUCONEST and Joenja uptake plus geographic expansion.
See our latest analysis for Pharming Group.
The raised guidance follows a strong run in Pharming Group’s share price. The company has recorded a 30 day share price return of 15.21% and a 90 day share price return of 33.06%,...